On April 6, Casey Ross of STAT PLUS published a deep-dive aritcle on United Healthcare's massive investments in AI.
See the subscription article here:
I don't want to infringe on his article, so here are just a couple highlights.
###
This is not “AI in health care” in the abstract; it is AI moving into the claims payment stack.
The key point is not that UnitedHealth has a chatbot. The key point is that AI is being inserted into claims adjudication, coding, fraud edits, prior authorization workflow, and coverage-facing operations. That places AI very close to the actual machinery that determines whether care is paid, delayed, downcoded, or denied.United is using AI not only as an insurer tool, but as a market-facing platform product.
Through Optum, United is not merely optimizing internal workflow. It is also selling AI-enabled tools outward to providers and other payers. That matters because United is shaping the reimbursement environment both as a plan and as a vendor of operational infrastructure. In policy terms, that raises the stakes from a company story to a system architecture story.The article points to the emergence of an “algorithmic arms race” around payment integrity and coding.
United is applying AI to billing codes, claims review, fraud detection, and prior auth. Patients and providers may hear the language of efficiency, but the reimbursement subtext is clear: AI can be used to accelerate edits, intensify scrutiny, standardize utilization controls, and tighten payment leakage. That may reduce administrative waste, but it also creates new ways to industrialize adverse payment outcomes at scale.The central policy problem is not whether AI is present, but whether it is auditable.
United says physicians—not AI—make medical necessity decisions, and it describes an internal responsible-AI review board. But the article underscores the practical problem: patients and providers often cannot see what the algorithm did, what inputs it relied on, how much human review occurred, or whether AI shaped the decision path upstream. In reimbursement policy, that is the difference between ordinary utilization management and a potentially opaque new form of automated coverage control.CMS, state regulators, and courts will eventually have to decide whether AI-assisted payment decisions need a new disclosure and accountability framework.
The article describes a world in which AI deployment is racing ahead while regulation remains patchy. That is unlikely to be stable. One can easily imagine future pressure for rules requiring disclosure of when AI was used, what role it played in denials or edits, what error rates were observed, what specialty oversight existed, and what appeal rights attach. For reimbursement policy, this could become as important as prior authorization reform, audit transparency, or program-integrity guardrails.
